Dupilumab, the first biologic agent approved by the Food and Drug Administration (FDA) in 2020 for the treatment of pediatric patients aged ≥ 6 with moderate-to-severe AD, targets the IL-4Rα subunit and inhibits inflammatory responses by blocking the signaling of IL-4 and IL-13 [15–18]. The gene discussed is IL13; the disease is Alzheimer disease.